News
Stay Up-To-Date on NEXT Oncology
- All
- NEXT Oncology Blog
- NEXT Oncology News
- Press Releases
Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place
In oncology clinical trials, many patients spend their final months at a central clinical trial facility far from home for “mandatory” protocol visits/diagnostic testing. Studies suggest that the travel strain …
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the Group …
MBrace Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial Evaluating Investigational Antibody-Drug Conjugate MBRC-101
MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the successful initiation of patient …
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today …
Dr Sommerhalder on the Potential Utility of Single-Agent RMC-6291 in KRAS G12C–Mutant CRC
David Sommerhalder, MD, medical oncologist, hematologist, Texas Oncology, director, Clinical Research, NEXT Oncology, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer (CRC). Read the full …
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms …
Incendia Therapeutics Announces Upcoming Presentations at the European Society for Medical Oncology Congress 2023
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Incendia Therapeutics, formerly Parthenon Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will …
NEXT Oncology and MediLink Team Up on Phase 1 Clinical Trial
FOR IMMEDIATE RELEASE DATE: October 9, 2023 Contact: Lisa Owens, 210-601-6647 NEXT Oncology and MediLink Therapeutics Take “Team Approach” to Next Level on Phase 1 First in Human Clinical Trial …
Solid Tumors: First-in-human trial of CBX-12 an Alphalex PDC
Ismael Rodriguez Rivera, MD, Medical Oncologist and Clinical Investigator from NEXT Oncology, has conducted a groundbreaking study on a novel therapeutic approach for patients with advanced or metastatic solid tumors. Read …
ZielBio to Present Interim Findings from its Phase 1/2
ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases, will present the first set of clinical data from its lead asset, ZB131, directed …